Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study Evaluating Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children
Latest Information Update: 04 Jun 2024
At a glance
- Drugs MinL 4.0 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors Codagenix
- 30 May 2024 Planned End Date changed from 5 Jun 2024 to 27 Jun 2025.
- 30 May 2024 Planned primary completion date changed from 1 Dec 2023 to 30 Apr 2025.
- 10 May 2023 According to Codagenix media release, company initiates dosing in this study.